Galapagos (Biotechnology) Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
704
- Stock Symbol
-
GLPG
- Investments
-
14
- Share Price
-
$24.89
- (As of Thursday Closing)
Galapagos (Biotechnology) General Information
Description
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Contact Information
Website
www.glpg.comCorporate Office
- Generaal De Wittelaan L11 A3
- 2800 Mechelen
- Belgium
Corporate Office
- Generaal De Wittelaan L11 A3
- 2800 Mechelen
- Belgium
Galapagos (Biotechnology) Stock Performance
As of 17-Apr-2025, Galapagos (Biotechnology)’s stock price is $24.89. Its current market cap is $1.64B with 65.9M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $24.89 | $24.48 | $21.97 - $32.15 | $1.64B | 65.9M | 106K | $1.21 |
Galapagos (Biotechnology) Financials Summary
As of 31-Dec-2024, Galapagos (Biotechnology) has a trailing 12-month revenue of $298M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (1,897,764) | (1,897,764) | (1,322,361) | (1,363,424) |
| Revenue | 298,279 | 298,279 | 259,399 | 253,650 |
| EBITDA | (50,261) | (50,261) | (30,916) | (14,953) |
| Net Income | 80,164 | 80,164 | 229,072 | (229,196) |
| Total Assets | 4,303,513 | 4,303,513 | 4,816,665 | 5,077,106 |
| Total Debt | 12,198 | 12,198 | 10,607 | 23,487 |
Galapagos (Biotechnology) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Galapagos (Biotechnology) Comparisons
Industry
Financing
Details
Galapagos (Biotechnology) Competitors (77)
One of Galapagos (Biotechnology)’s 77 competitors is Idorsia Pharmaceuticals, a Corporate Backed or Acquired company based in Allschwil, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Idorsia Pharmaceuticals | Corporate Backed or Acquired | Allschwil, Switzerland | ||||
| Ardelyx | Formerly VC-backed | Fremont, CA | ||||
| Coherus Biosciences | Formerly VC-backed | Redwood City, CA | ||||
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Galapagos (Biotechnology) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Galapagos (Biotechnology) Patents
Galapagos (Biotechnology) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4519263-A1 | Sulfonamide compounds and pharmaceutical compositions thereof for the treatment of neurodegenerative disorders | Pending | 05-May-2022 | ||
| CA-3225221-A1 | Treatment of inflammatory diseases | Pending | 12-Jul-2021 | ||
| AU-2022310901-A1 | Treatment of inflammatory diseases | Pending | 12-Jul-2021 | ||
| JP-2024524631-A | Treatment of inflammatory diseases | Pending | 12-Jul-2021 | ||
| EP-4370128-A1 | Treatment of inflammatory diseases | Pending | 12-Jul-2021 | A61K31/5377 |
Galapagos (Biotechnology) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Galapagos (Biotechnology) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Galapagos (Biotechnology) Investments & Acquisitions (14)
Galapagos (Biotechnology)’s most recent deal was a Later Stage VC with Frontier Medicines for . The deal was made on 26-Feb-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Frontier Medicines | 26-Feb-2024 | Later Stage VC | Drug Discovery | ||
| AboundBio | 21-Jun-2022 | Merger/Acquisition | Biotechnology | ||
| CellPoint (Biotechnology) | 21-Jun-2022 | Merger/Acquisition | Biotechnology | ||
| Fibrocor Therapeutics | 15-Jan-2020 | Early Stage VC | Drug Discovery | ||
| VitalNext | 04-Jul-2013 | Early Stage VC | Pharmaceuticals |
Galapagos (Biotechnology) ESG
Risk Overview
Risk Rating
Updated September, 05, 2024
29.71 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Galapagos (Biotechnology) Exits (2)
Galapagos (Biotechnology)’s most recent exit was on 02-Feb-2010 from Argenta Discovery. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Argenta Discovery | 02-Feb-2010 | Completed |
|
||
| BioFocus DPI | 24-Oct-2005 | Merger/Acquisition | Completed |
Galapagos (Biotechnology) Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Galapagos Biopharma Sweden | Stockholm, Sweden | 2021 | |
| CellPoint (Biotechnology) | Oegstgeest, Netherlands | 2018 | |
| Galapagos (Drug Discovery and Research Activities in Romainville, France) | Romainville, France | 2001 | |
| Inpharmatica | London, United Kingdom | 1998 | |
| SpinCo (Galapagos) |
Galapagos (Biotechnology) FAQs
-
When was Galapagos (Biotechnology) founded?
Galapagos (Biotechnology) was founded in 1999.
-
Where is Galapagos (Biotechnology) headquartered?
Galapagos (Biotechnology) is headquartered in Mechelen, Belgium.
-
What is the size of Galapagos (Biotechnology)?
Galapagos (Biotechnology) has 704 total employees.
-
What industry is Galapagos (Biotechnology) in?
Galapagos (Biotechnology)’s primary industry is Biotechnology.
-
Is Galapagos (Biotechnology) a private or public company?
Galapagos (Biotechnology) is a Public company.
-
What is Galapagos (Biotechnology)’s stock symbol?
The ticker symbol for Galapagos (Biotechnology) is GLPG.
-
What is the current stock price of Galapagos (Biotechnology)?
As of 17-Apr-2025 the stock price of Galapagos (Biotechnology) is $24.89.
-
What is the current market cap of Galapagos (Biotechnology)?
The current market capitalization of Galapagos (Biotechnology) is $1.64B.
-
What is Galapagos (Biotechnology)’s current revenue?
The trailing twelve month revenue for Galapagos (Biotechnology) is $298M.
-
Who are Galapagos (Biotechnology)’s competitors?
Idorsia Pharmaceuticals, Ardelyx, Coherus Biosciences, Biogen, and ACADIA Pharmaceuticals are some of the 77 competitors of Galapagos (Biotechnology).
-
What is Galapagos (Biotechnology)’s annual earnings per share (EPS)?
Galapagos (Biotechnology)’s EPS for 12 months was $1.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
